The Benefits of Real-Time Nonclinical Safety Data Analysis

Reviewing data from ongoing nonclinical drug safety studies enables toxicologists to:

Monitor findings as the study progresses
Adjust study designs in real-time
Provide feedback to the drug development team to inform decision-making.

Unfortunately, performing data analysis and visualization while the study is ongoing can be challenging. Contract research organizations (CROs) conduct many of these studies, and they may not provide interim study data to sponsors. If interim data is available, they may be in a format unsuitable for analysis and visualization.

The SEND (Standard for Exchange of Nonclinical Data) format is used for animal data collected in nonclinical toxicology studies. Our white paper explores how the right software helps toxicologists perform real-time data analysis and visualization to make faster, smarter decisions.

Download the white paper now for immediate insights on how to perform more efficient toxicology testing, faster, thus helping accelerate the pace of drug development.

What you’ll learn

How real-time data access speeds up drug safety decisions

The role of SEND in streamlining data integration and compliance

Ways visualization tools enhance data analysis and communication

Strategies for effective collaboration with CROs for interim data access

About the authors

Peggy Zorn

Senior Director, Product Management

Peggy is the Customer Success lead for SEND Explorer. She has a strong background in nonclinical data management, warehousing and the SEND standard, including serving as the lead of the CDISC SEND controlled terminology team for over 7 years. She continues to be involved in the CDISC SEND team as well as the PhUSE nonclinical working group.

Prior to joining Certara, Peggy worked for 15 years at Pfizer, with 6 of those years focused on nonclinical data management and warehousing. She also worked for INDS for several years, which is the company that originally developed the SEND Explorer dataset reviewer and visualization tool.

Download the white paper

Learn the benefits of real-time nonclinical safety data analysis. Submit the form below to download the white paper!

About Certara

Certara is dedicated to transforming drug discovery and development for good. We harness the power of biosimulation, advanced analytics, and regulatory expertise to create a future where treatments reach patients faster and more efficiently.

From discovery to market access and commercial, we tailor solutions to meet our clients’ most pressing challenges. Through strategic leadership and advanced predictive technologies, Certara provides comprehensive solutions to optimize drug development processes, reduce risks, and improve outcomes. Our clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.